BioTrinity 2014 saw more senior business development involvement from Global Pharma and even more involvement from Corporate Venture funds with an ever great number of the key players being represented from both their BD&L and investment sides principally attending to look for in-licensing M&A and investment opportunities.

BioTrinity 2014 stats:

  • 80 global pharma/corporate venture delegates
  • 33 global pharma/medical technology corporates

2015 participating Global Pharma and MedTech Corporates to date:

  • AbbVie Deutschland GmbH & Co. KG, Collaborations Dept
  • Amgen, Executive Director of Corporate Development
  • Amgen, Executive Director, Transactions Europe/Russia
  • AstraZeneca, VP Strategy & Externalisation
  • AstraZeneca, VP Strategic Partnering & Business Development
  • Boehringer Ingelheim GmBH, VP Boehringer Ingelheim Venture Fund
  • Bristol-Myers Squibb, Vice President, Business Development
  • Eli Lilly and Company, VP Search & Evaluation Europe, Corporate Business Development
  • Ferrer Internacional SA, Licensing Director
  • J&J Innovation, Senior Director, Partnership Management
  • Novo Nordisk, Innovation Sourcing Director
  • Philips, Head Commercial Operations, Handheld Diagnostics, Healthcare Incubator
  • Shire Pharmaceutical, Senior Director, Scientific Licensing
  • Sigma Aldrich, Account Manager
  • Takeda Pharmaceuticals International Inc, VP Search & Evaluation
  • Teijin Pharma Ltd, General Manager

 

 

 





BioTrinity 2014 highlights
1,014 delegates from 32 countries
624 companies
184 speakers
107 company showcase presentations
2,462 one-to-one meetings
130+ investor delegates from 12 countries
61 exhibitors
86 global pharma/medtech delegates
33 corporate venture delegates